Risk factors and clinical significance of invasive infections caused by levofloxacin-resistant Streptococcus pneumoniae

Infection

Volumn 41, Issue 5, 2013, Pages 935-939

  Isea Pena M C ^a   Sanz Moreno, J C ^b   Esteban, J ^a   Fernandez Roblas R ^a   Fernandez Guerrero M L ^c  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Clinical Microbiology Unit   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Bacteremia; Levofloxacin; Pneumonia; Streptococcus pneumoniae

Indexed keywords

CEFOTAXIME; CHLORAMPHENICOL; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN DERIVATIVE; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; CONTROLLED STUDY; DISK DIFFUSION; EPSILOMETER TEST; FEMALE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LATEX AGGLUTINATION TEST; LEVOFLOXACIN RESISTANT STREPTOCOCCUS PNEUMONIAE; LEVOFLOXACIN SUSCEPTIBLE STREPTOCOCCUS PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MORTALITY; NONHUMAN; PERICARDITIS; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; QUELLUNG REACTION; RETROSPECTIVE STUDY; RISK FACTOR; SEROTYPING; SMOKING; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LEVOFLOXACIN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMONIA, PNEUMOCOCCAL; RETROSPECTIVE STUDIES; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE;

EID: 84885171934     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0481-4     Document Type: Article

References (20)

1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27-72.
2. Patel SN, McGeer A, Melano R, Tyrrell GJ, Green K, Pillai DR, et al.; Canadian Bacterial Surveillance Network. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Antimicrob Agents Chemother. 2011;55:3703-8.
3. Simoens S, Verhaegen J, van Bleyenbergh P, Peetermans WE, Decramer M. Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones. Antimicrob Agents Chemother. 2011;55:3051-3.
4. Fenoll A, Granizo JJ, Aguilar L, Giménez MJ, Aragoneses-Fenoll L, Hanquet G, et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol. 2009;47:1012-20.
5. Low DE. Fluoroquinolone-resistant pneumococci: maybe resistance isn't futile? Clin Infect Dis. 2005;40:236-8.
6. Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Rice CL, Doern GV. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis. 2005;40:225-35.
7. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1, 2013. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Breakpoint- tables/Breakpoint-table-v-3.1.xls (2013).
8. Davies TA, Evangelista A, Pfleger S, Bush K, Sahm DF, Goldschmidt R. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob Agents Chemother. 2002;46:119-24.
9. Dalhoff A. Resistance surveillance studies: a multifaceted problem - the fluoroquinolone example. Infection. 2012;40:239-62.
10. Lim S, Bast D, McGeer A, de Azavedo J, Low DE. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis. 2003;9:833-7.
11. Adam HJ, Schurek KN, Nichol KA, Hoban CJ, Baudry TJ, Laing NM, et al. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob Agents Chemother. 2007;51:198-207.
12. de la Campa AG, Ardanuy C, Balsalobre L, Pérez-Trallero E, Marimón JM, Fenoll A, et al. Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg Infect Dis. 2009;15:905-11.
13. Rodríguez-Avial I, Ramos B, Ríos E, Cercenado E, Ordobás M, Sanz JC; Madrid Streptococcus pneumoniae Microbiological Group. Clonal spread of levofloxacin-resistant Streptococcus pneumoniae invasive isolates in Madrid, Spain, 2007 to 2009. Antimicrob Agents Chemother. 2011;55:2469-71.
14. Sanz JC, Cercenado E, Marín M, Ramos B, Ardanuy C, Rodríguez-Avial I, et al. Multidrug-resistant pneumococci (serotype 8) causing invasive disease in HIV+ patients. Clin Microbiol Infect. 2011;17:1094-8.
15. Ho PL, Tse WS, Tsang KW, Kwok TK, Ng TK, Cheng VC, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis. 2001;32:701-7.
16. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A; Toronto Invasive Bacterial Disease Network. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis. 2005;40:1288-97.
17. von Gottberg A, Klugman KP, Cohen C, Wolter N, de Gouveia L, du Plessis M, et al.; Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA). Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet. 2008;371:1108-13.
18. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:747-50.
19. Pérez-Trallero E, Marimón JM, González A, Ercibengoa M, Larruskain J. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. Clin Infect Dis. 2005;41:560-4.
20. Kang CI, Song JH, Kim SH, Chung DR, Peck KR, Thamlikitkul V, et al.; Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group. Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort. Infection. 2013;41:151-7.